



State of New Jersey
Department of Human Services
Division of Medical Assistance & Health Services

NEWSLETTER

Volume 33 No. 01

January 2023

TO: Providers of Pharmaceutical Services - **For Action**
Health Maintenance Organizations - **For Information Only**

SUBJECT: New Jersey Department of Human Services (DHS) initiative to provide free naloxone anonymously to any NJ resident, regardless of their NJ FamilyCare (NJFC)/Medicaid eligibility.

EFFECTIVE: Claims with service dates on or after January 1, 2023

PURPOSE: To notify providers of pharmaceutical services of the DHS initiative to provide free naloxone anonymously to any NJ resident fourteen (14) years of age or older regardless of their NJFC/Medicaid eligibility.

BACKGROUND: Opioid-related overdose deaths continue to rise at an alarming rate throughout the country and within New Jersey. To address this crisis, DHS has taken unprecedented steps to curb the use and misuse of opioids by expanding access to prevention and treatment services, removing access barriers to opioid reversal medications, and equipping first responders, health care professionals, and communities at-large with the resources needed to treat overdoses and reduce overdose deaths. New Jersey will be the first state in the nation to allow any resident to anonymously receive free naloxone from a pharmacy at any time. This program will be known as "Naloxone365."

ACTION: Effective for service dates on or after January 1, 2023, pharmacies may dispense free naloxone to any NJ resident, fourteen (14) years of age or older, anonymously regardless of their NJFC/Medicaid eligibility, pursuant to the Department of Health (DOH) standing order currently in effect ([Control Number 2021-01](#)).

The New Jersey Board of Pharmacy will be issuing guidance for pharmacies wishing to participate in this program.

In order for pharmacies to request NJFC/Medicaid Fee-For-Service (FFS) payment consideration for anonymous naloxone dispensing, the following billing requirements shall apply:

- Pharmacies must bill naloxone claims to BIN 610515. Other NJFC/Medicaid billing requirements shall not apply for naloxone provided through Naloxone365.
- Pharmacies must report a first name of "Jane" in the NCPDP *Patient First Name* field (310-CA), and a last name of "Doe" in the NCPDP *Patient Last Name* field (311-CB).

- Pharmacies must report a date of birth of “010199” in the NCPDP *Date of Birth* field (304-C4).
- Pharmacies must report the twelve (12) byte recipient ID 580200000020 broken out across two (2) fields: the ten (10) byte *Cardholder ID* field and the two (2) byte *Person Code* field.
- Pharmacies must populate the NCPDP *Prescriber ID* field (411-DVB) with the National Provider Identifier (NPI) issued by the New Jersey Department of Health. Please refer to the [DOH website](#) for current standing order requirements.
- All available FDA-approved four (4) mg naloxone nasal spray products are covered for anonymous dispensing.
- Only one (1) package of naloxone containing two (2) sprays shall be covered per dispense. Each package dispensed requires its own unique prescription number.
- There is no limit to the number of naloxone products that may be dispensed per week.
- Anonymous coverage of naloxone products is intended only for community residents and is not available for nursing facility residents.

Note: This program applies to all New Jerseyans, including NJ FamilyCare/Medicaid members, when naloxone is requested anonymously. When naloxone is prescribed for a specific NJ FamilyCare/Medicaid-eligible member using their Medicaid member ID number, existing billing requirements shall still apply.

The DMAHS may retrospectively review claims and request invoices for naloxone and recover any inappropriately-paid claims.

Please refer to the [DOH website](#) for current and updated standing order requirements: <https://www.nj.gov/health/integratedhealth/home/naloxone.shtml#1>

Please contact the Gainwell Technologies Provider Services Unit at 1-800-776-6334 for any questions regarding this Newsletter.

RETAIN THIS NEWSLETTER FOR FUTURE REFERENCE